PMID- 28848911
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2372-952X (Print)
IS  - 2372-952X (Electronic)
IS  - 2372-952X (Linking)
VI  - 4
IP  - 1
DP  - 2016 Dec 24
TI  - Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease 
      Management and Prevention Program.
PG  - 56-64
LID - 10.15326/jcopdf.4.1.2016.0161 [doi]
AB  - Rationale: Alpha-1 antitrypsin deficiency (AATD) is characterized by decreased 
      circulating levels or activity of the serum protein, alpha-1 antitrypsin, which 
      increases risk for chronic lung or liver injury and may lead to diseases such as 
      chronic obstructive pulmonary disease (COPD). Currently there is no cure for 
      AATD, and it is largely controlled through disease management and augmentation 
      therapy. This study was designed to describe characteristics of patients enrolled 
      in a disease management and prevention program. Methods: Data from questionnaires 
      administered by AlphaNet were obtained on 4747 AATD patients and included 
      demographic information, medical history, lifestyle choices, and adherence to the 
      Alpha-1 Disease Management and Prevention Program (ADMAPP). A total of 1221 
      participants (25.72%) had missing adherence information and were excluded, 
      leaving a final study population of 3526. Questionnaire answer dates ranged from 
      May 29, 2008 to February 14, 2015. Logistic regression was used to adjust for 
      demographic factors and comorbidities, comparing the populations stratified by 
      adherence to ADMAPP. Results: After adjustment for age, sex, race, Charlson 
      Comorbidity Index, and income level, individuals who self-reported any adherence 
      to ADMAPP were more likely to feel informed about their condition (odds 
      ratio[OR](adj) 4.95, 95% confidence interval[CI][3.24, 7.57]), and be taking 
      preventive measures, such as smoking cessation (OR(adj) 0.47, 95% CI [0.31, 
      0.70]), appropriate immunizations, and self-reported exercise (OR(adj) 2.07, 95% 
      CI [1.74, 2.47]). Conclusions: This study suggests that ADMAPP may be a useful 
      tool for informing and improving preventive measures taken by individuals with 
      AATD. Future studies are needed to clarify the observed associations and study 
      additional outcomes.
FAU - Perkins, Jordan T
AU  - Perkins JT
AD  - Department of Preventive Medicine and Environmental Health, University of 
      Kentucky College of Public Health, Lexington.
FAU - Choate, Radmila
AU  - Choate R
AD  - Department of Preventive Medicine and Environmental Health, University of 
      Kentucky College of Public Health, Lexington.
FAU - Mannino, David M
AU  - Mannino DM
AD  - Department of Preventive Medicine and Environmental Health, University of 
      Kentucky College of Public Health, Lexington.
AD  - Department of Epidemiology, University of Kentucky College of Public Health, 
      Lexington.
FAU - Browning, Stephen R
AU  - Browning SR
AD  - Department of Epidemiology, University of Kentucky College of Public Health, 
      Lexington.
FAU - Sandhaus, Robert A
AU  - Sandhaus RA
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, 
      Denver, Colorado.
LA  - eng
PT  - Journal Article
DEP - 20161224
PL  - United States
TA  - Chronic Obstr Pulm Dis
JT  - Chronic obstructive pulmonary diseases (Miami, Fla.)
JID - 101635411
PMC - PMC5560250
OTO - NOTNLM
OT  - AATD
OT  - alpha-1 antitrypsin deficiency
OT  - chronic obstructive pulmonary disease
OT  - copd
COIS- DM has received honoraria/consulting fees and served on speaker bureaus for 
      GlaxoSmithKline PLC, Novartis Pharmaceuticals, Pfizer Inc., Boehringer-Ingelheim, 
      AstraZeneca PLC, Forest Laboratories Inc., Merck, Amgen, and Sunovion. 
      Furthermore, he has received royalties from Up-to-Date, is on the Board of 
      Directors of the COPD Foundation, and has been compensated as a medical expert in 
      legal cases. JTP, RC, and SRB report no conflicts of interest. RAS has received 
      research funding from Grifols, CSL Behring, AstraZeneca, and the National 
      Institutes of Health/National Heart Lung and Blood Institute. He has served as an 
      advisor or consultant for Grifols, CSL Behring, Baxter, AstraZeneca, and Alnylam. 
      He is on the Board of Directors of AlphaNet and a member of the Medical and 
      Scientific Advisory Committee of the COPD Foundation and is the medical director 
      of the Alpha-1 Foundation and AlphaNet.
EDAT- 2017/08/30 06:00
MHDA- 2017/08/30 06:01
PMCR- 2016/12/24
CRDT- 2017/08/30 06:00
PHST- 2017/08/30 06:00 [entrez]
PHST- 2017/08/30 06:00 [pubmed]
PHST- 2017/08/30 06:01 [medline]
PHST- 2016/12/24 00:00 [pmc-release]
AID - 10.15326/jcopdf.4.1.2016.0161 [doi]
PST - epublish
SO  - Chronic Obstr Pulm Dis. 2016 Dec 24;4(1):56-64. doi: 
      10.15326/jcopdf.4.1.2016.0161.